These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24081887)

  • 1. Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany.
    Eidt-Koch D; Wagner TO; Mittendorf T; Reimann A; von der Schulenburg JM
    Pediatr Pulmonol; 2011 Mar; 46(3):278-85. PubMed ID: 24081887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].
    Eidt D; Mittendorf T; Wagner TO; Reimann A; Graf von der Schulenburg JM
    Med Klin (Munich); 2009 Jul; 104(7):529-35. PubMed ID: 19618138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
    Heimeshoff M; Hollmeyer H; Schreyögg J; Tiemann O; Staab D
    Pharmacoeconomics; 2012 Sep; 30(9):763-77. PubMed ID: 22690685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.
    Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I
    Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient medication costs of patients with cystic fibrosis in Germany.
    Eidt-Koch D; Wagner TO; Mittendorf T; Graf von der Schulenburg JM
    Appl Health Econ Health Policy; 2010; 8(2):111-8. PubMed ID: 20175589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network.
    Huot L; Durieu I; Bourdy S; Ganne C; Bellon G; Colin C; Touzet S;
    J Cyst Fibros; 2008 Sep; 7(5):403-8. PubMed ID: 18358793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of care and clinical condition in paediatric cystic fibrosis patients.
    Baumann U; Stocklossa C; Greiner W; von der Schulenburg JM; von der Hardt H
    J Cyst Fibros; 2003 Jun; 2(2):84-90. PubMed ID: 15463855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of cystic fibrosis: analysis of treatment costs in a specialized center in northern Italy.
    Colombo C; Daccò V; Alicandro G; Loi S; Mazzi S; Lucioni C; Ravasio R
    Adv Ther; 2013 Feb; 30(2):165-75. PubMed ID: 23397400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].
    Baltin CT; Smaczny C; Wagner TO
    Med Klin (Munich); 2010 Dec; 105(12):887-900. PubMed ID: 21240588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare expenditures for privately insured people with cystic fibrosis.
    Ouyang L; Grosse SD; Amendah DD; Schechter MS
    Pediatr Pulmonol; 2009 Oct; 44(10):989-96. PubMed ID: 19768806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.
    Dewitt EM; Grussemeyer CA; Friedman JY; Dinan MA; Lin L; Schulman KA; Reed SD
    Value Health; 2012; 15(2):277-83. PubMed ID: 22433759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost of pharmacologic treatment and their determinants in ambulatory care of cystic fibrosis patients].
    Stelmach I; Korzeniewska A; Stelmach W
    Pneumonol Alergol Pol; 2004; 72(9-10):415-9. PubMed ID: 16021997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
    Wertz DA; Chang CL; Stephenson JJ; Zhang J; Kuhn RJ
    J Med Econ; 2011; 14(6):759-68. PubMed ID: 21942462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis.
    Durieu I; Dalon F; Reynaud Q; Lemonnier L; Dehillotte C; Bérard M; Walther D; Viprey M; Van Ganse E; Belhassen M
    J Cyst Fibros; 2022 Jan; 21(1):88-95. PubMed ID: 33865726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.
    Frey S; Stargardt T; Schneider U; Schreyögg J
    Pharmacoeconomics; 2019 Aug; 37(8):1029-1039. PubMed ID: 30949989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
    van Gool K; Norman R; Delatycki MB; Hall J; Massie J
    Value Health; 2013; 16(2):345-55. PubMed ID: 23538187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.
    Levy JF; Rosenberg MA; Farrell PM
    Pediatr Pulmonol; 2016 Dec; 51(12):1295-1303. PubMed ID: 27740724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
    Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
    Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Sansgiry SS; Joish VN; Boklage S; Goyal RK; Chopra P; Sethi S
    J Med Econ; 2012; 15(2):219-24. PubMed ID: 22084956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.